Press Release

« Back

Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting

December 11, 2018

EVANSTON, Ill., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced two upcoming poster presentations highlighting preclinical data on its novel NMDA receptor (NMDAr) modulator, NYX-2925, at the American College of Neuropsychopharmacology’s Annual Meeting in Hollywood, Florida.

“We are encouraged by the preclinical effects we see with NYX-2925 on synaptic plasticity and sleep architecture, both of which are known to be NMDA receptor mediated,” said Joseph Moskal, Ph.D., chief scientific officer at Aptinyx. “These robust preclinical data advance our understanding of this novel mechanism of action and inform our confidence in NYX-2925 as we explore its potential as a treatment for chronic pain.”

NYX-2925 is a novel NMDA receptor modulator currently in Phase 2 clinical development for the treatment of painful diabetic peripheral neuropathy (DPN) and under evaluation in an exploratory Phase 2 study in fibromyalgia. NYX-2925 has demonstrated robust activity in preclinical models of numerous neuropathic pain conditions with a favorable safety and tolerability profile. In a Phase 1 clinical study in healthy human subjects, NYX-2925 was well tolerated with no treatment related serious adverse events across a wide dose range, including dose levels well in excess of the expected therapeutic levels. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Aptinyx’s development of NYX-2925 for the treatment of neuropathic pain associated with DPN.

Presentation Details:

Presentation Title: NYX-2925 facilitates auditory-evoked long-term potentiation in rats: a translational approach for measuring NMDA receptor-mediated synaptic plasticity
(Poster Number: 156)
Presenter:Jeffrey Burgdorf, Ph.D., Aptinyx
Poster Presentation: Tuesday, December 11 at 5:30 p.m. ET

Presentation Title: Enhancement of synaptic plasticity by NYX-2925: Sleep cycle EEG studies in rats
(Poster Number: 142)
Presenter:Jeffrey Burgdorf, Ph.D., Aptinyx
Poster Presentation: Wednesday, December 12 at 5:30 p.m. ET

About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company’s business plans and objectives, therapeutic effects of the company’s product candidates, expectations regarding the design, implementation, enrollment, timing, and success of its current and planned clinical trials, expectations regarding its preclinical development activities, and expectations regarding its uses of capital. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the company’s product candidate development activities and planned clinical trials; the company’s ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; as well as those risks and uncertainties set forth in the company’s most recent quarterly report on Form 10-Q and in its other filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contacts:
Nick Smith
Aptinyx Inc.
ir@aptinyx.com
847-871-0377

Rachel Frank
Stern Investor Relations
rachelf@sternir.com
212-362-1200

Media Contact:
Jordann Phillips
Canale Communications
jordann@canalecomm.com
619-849-6009

 

AptinyxLogo_FullColor_RGB.jpg

Source: Aptinyx Inc.

Print Page RSS Email Alerts Investor Contacts